<DOC>
	<DOCNO>NCT00410033</DOCNO>
	<brief_summary>This trial conduct Europe . This single-centre , retrospective trial aim compare antibody level child adolescent .</brief_summary>
	<brief_title>Comparison Antibody Levels Children Adolescents After Initiation Insulin Therapy Either Insulin Aspart Soluble Human Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Informed consent obtain trialrelated activity Any subject onset Type 1 Diabetes Treatment either Insulin Aspart Soluble Human Insulin Soluble Human Insulin Isophane Human Insulin / MixtardÂ® least 9 month time diagnosis diabetes Treatment immunosuppressive agent For Insulin Aspart + Isophane Human Insulin : Treatment insulin analogue Insulin Aspart treatment fast act human insulin period 7 day treatment period For Soluble Human Insulin Isophane Human Insulin group : Treatment insulin analogues Other disease influence immune response Unable unwilling provide consent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>